Get the Stockscreener App
4.48
3.94%
0.17
Pre-market:
4.50
0.02
+0.45%
Vanda Pharmaceuticals Inc stock is traded at $4.48, with a volume of 391.72K.
It is up +3.94% in the last 24 hours and down -7.63% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
See More
Previous Close:
$4.31
Open:
$4.31
24h Volume:
391.72K
Relative Volume:
0.64
Market Cap:
$261.22M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
85.50
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
+0.90%
1M Performance:
-7.63%
6M Performance:
-17.04%
1Y Performance:
+23.42%
1-Day Range:
$4.23
$4.48
1-Week Range:
$4.215
$4.61
52-Week Range:
$3.46
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.48 | 261.22M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder - The Business Journals
HC Wainwright Reaffirms Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - Pharmaceutical Technology
Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab - MSN
Vanda, Anaptys Join on Development Pact - Baystreet.ca
AnaptysBio Partners with Vanda for Imsidolimab Development - TipRanks
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab - Marketscreener.com
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab - TipRanks
Breakthrough GPP Treatment Deal: Vanda Secures Phase 3-Ready Rare Disease Drug for $15M Upfront - StockTitan
Indo-Asian News Service - IANS India Pvt Ltd
Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from HC Wainwright - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock - MSN
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug - MSN
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock By Investing.com - Investing.com Canada
Washington D.C. Pharma Co. Receives FDA Acceptance - Streetwise Reports
US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts - Benzinga
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts - The Business Journals
Vanda granted hearing to discuss FDA rejection of application for tradipitant - MSN
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug By Investing.com - Investing.com South Africa
Vanda granted hearing to discuss FDA rejection of application for tradipitant ( - Seeking Alpha
Vanda Pharmaceuticals Files New Drug Application - TipRanks
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA - TipRanks
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis - PR Newswire
Vanda Loses US Trade Secrets Battle Over Fanapt And Hetlioz Generics - News & Insights
US Claims Court rules Vanda’s trade secrets not so secret - BioWorld Online
Vanda Loses US Trade Secrets Battle On Fanapt And Hetlioz ANDA Products - News & Insights
Equities Analysts Issue Forecasts for VNDA FY2025 Earnings - MarketBeat
Vanda Loses Takings Clause Arguments In Trade Secret Fight - Law360
Vanda Pharmaceuticals (NASDAQ:VNDA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com - MarketBeat
Vanda asserts FDA review of tradipitant was flawed - MSN
Insomnia Market Overall Study Report 2025-2032 | Vanda - openPR
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate - Yahoo Finance
Pugilistic Vanda Collects Another NOOH As US FDA Defends Tradipitant Turndown - News & Insights
DC Circuit Skeptical of FDA Rejection of Vanda’s Jet Lag Drug - Bloomberg Law
High Court Rejects Vanda Suit Over Medicaid Drug Definition - Bloomberg Law
Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review - BioSpace
Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner - Marketscreener.com
Vanda Pharmaceuticals Challenges FDA Over Gastroparesis Drug Rejection in Open Letter - StockTitan
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now? - Yahoo Finance
StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):